Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety

2010 ◽  
Vol 5 (5) ◽  
pp. 627-649 ◽  
Author(s):  
Terry A Jacobson ◽  
Peter H Jones ◽  
Eli M Roth
Keyword(s):  
Combination Therapy ◽  
Efficacy And Safety ◽  
Fenofibric Acid ◽  
Mixed Dyslipidemia

Efficacy and Safety of Fenofibric Acid and Rosuvastatin Combination Therapy in Women 55 Years or Older (Post-Menopausal) with Mixed Dyslipidemia

2009 ◽  
Vol 3 (3) ◽  
pp. 221-222 ◽  
Author(s):  
Anne Carol Goldberg ◽  
Nanette K. Wenger ◽  
Dawn M. Carlson ◽  
Maureen T. Kelly ◽  
Carolyn M. Setze ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Efficacy And Safety ◽  
Fenofibric Acid ◽  
Mixed Dyslipidemia ◽  
Post Menopausal

One-Year Efficacy and Safety of Rosuvastatin + Fenofibric Acid Combination Therapy in Patients with Mixed Dyslipidemia

2012 ◽  
Vol 12 (2) ◽  
pp. 117-125 ◽  
Author(s):  
Keith C. Ferdinand ◽  
Michael H. Davidson ◽  
Maureen T. Kelly ◽  
Carolyn M. Setze
Keyword(s):  
Combination Therapy ◽  
Efficacy And Safety ◽  
Fenofibric Acid ◽  
Mixed Dyslipidemia ◽  
One Year

Abstract: 517 EFFICACY AND SAFETY OF FENOFIBRIC ACID IN COMBINATION WITH ATORVASTATIN AND EZETIMIBE IN PATIENTS WITH MIXED DYSLIPIDEMIA: A PHASE 3 STUDY

2009 ◽  
Vol 10 (2) ◽  
pp. e262-e263
Author(s):  
P Jones ◽  
A Goldberg ◽  
H Knapp ◽  
M Kelly ◽  
C Setze ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Fenofibric Acid ◽  
Phase 3 ◽  
Mixed Dyslipidemia

scholarly journals Rosuvastatin and Fenofibrate Combination in The Treatment of Mixed Hyperlipidemia: A Narrative Review

2021 ◽  
Vol 4 (03) ◽  
pp. 867-877
Author(s):  
Kaushik Biswas ◽  
Ajoy Tiwari ◽  
Prachi Jadhav ◽  
Amit Goel ◽  
G V Chanukya
Keyword(s):  
Cardiovascular Risk ◽  
Combination Therapy ◽  
Fenofibric Acid ◽  
Cardiovascular Risk Reduction ◽  
Residual Cardiovascular Risk ◽  
Statin Monotherapy ◽  
Mixed Dyslipidemia ◽  
Lipid Control ◽  
Patient At Risk ◽  
Mixed Hyperlipidemia

Introduction: Patients with mixed dyslipidemia are presented with high levels of low-density lipid cholesterol (LDL-C), triglycerides (TG), and reduced high-density lipid cholesterol (HDL-C). Though useful in lowering LDL-C, therapy with rosuvastatin is insufficient in optimizing the overall lipid profile, thus putting the patient at risk of residual cardiovascular risk. A combination of statin with other lipid-modifying agents has been used with more efficient lipid control and cardiovascular risk prevention. Of these, fenofibric acid is the most frequently used, along with rosuvastatin. Methods: Authors conducted a literature search of published literature to assess the use of rosuvastatin and fenofibrate combination in the management of mixed hyperlipidaemia. Results and discussion: The authors selected a total of 46 articles to be included in the review. Due to the small number of articles and heterogeneity on the combination of rosuvastatin and fenofibrate combination in mixed hyperlipidemia, the findings herein are presented using narrative summaries. Based on the thorough assessment of the selected literature, the essential themes that emerged from the review include safety and efficacy of rosuvastatin and fenofibrate combination, place of therapy of rosuvastatin, and fenofibrate combination, and potential cardiovascular risk reduction with rosuvastatin and fenofibrate combination.   Conclusion: Based on the review, the authors suggested that the combination therapy with fenofibric acid was beneficial, well-tolerated with a similar safety profile compared with statin monotherapy. The combination therapy of moderate dose rosuvastatin and fenofibric acid led to a reduction of cardiovascular risk factors via several pathways.

scholarly journals LPLgene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia

2012 ◽  
Vol 53 (3) ◽  
pp. 556-560 ◽  
Author(s):  
Ariel Brautbar ◽  
Salim S. Virani ◽  
John Belmont ◽  
Vijay Nambi ◽  
Peter H. Jones ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Combination Therapy ◽  
Randomized Clinical Trial ◽  
Fenofibric Acid ◽  
Mixed Dyslipidemia

214: Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination with Rosuvastatin in Patients with Mixed Dyslipidemia: A Phase 3 Study

2008 ◽  
Vol 2 (3) ◽  
pp. 218-219 ◽  
Author(s):  
Peter H. Jones ◽  
Susan M. Buttler ◽  
Michael H. Davidson ◽  
Moti L. Kashyap ◽  
Maureen T. Kelly ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Fenofibric Acid ◽  
Phase 3 ◽  
Mixed Dyslipidemia

Efficacy and Safety of Rosuvastatin 5 mg in Combination with Fenofibric Acid 135 mg in Patients with Mixed Dyslipidemia – A Phase 3 Study

2010 ◽  
Vol 24 (5-6) ◽  
pp. 421-428 ◽  
Author(s):  
Eli M. Roth ◽  
Robert S. Rosenson ◽  
Dawn M. Carlson ◽  
Sandra M. Fukumoto ◽  
Carolyn M. Setze ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Fenofibric Acid ◽  
Phase 3 ◽  
Mixed Dyslipidemia

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study

2009 ◽  
Vol 157 (1) ◽  
pp. 195-203 ◽  
Author(s):  
Syed M. Mohiuddin ◽  
Carl J. Pepine ◽  
Maureen T. Kelly ◽  
Susan M. Buttler ◽  
Carolyn M. Setze ◽  
...  
Keyword(s):  
Randomized Controlled Study ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Fenofibric Acid ◽  
Phase 3 ◽  
Randomized Controlled ◽  
Mixed Dyslipidemia

The Efficacy and Safety of 12-Week Treatment with Fenofibric Acid Co-Administered with Statins in Patients 65 Years or Older with Mixed Dyslipidemia

2009 ◽  
Vol 3 (3) ◽  
pp. 215-216 ◽  
Author(s):  
Peter H. Jones ◽  
Mark S. Kipnes ◽  
Maria L. Rios ◽  
Carolyn M. Setze ◽  
Maureen T. Kelly ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Fenofibric Acid ◽  
Mixed Dyslipidemia
Sign in / Sign up

Export Citation Format

Share Document